Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Prepaid Assets (2021 - 2026)

Zentalis Pharmaceuticals has reported Prepaid Assets over the past 6 years, most recently at $10.4 million for Q1 2026.

  • For Q1 2026, Prepaid Assets fell 24.23% year-over-year to $10.4 million; the TTM value through Mar 2026 reached $10.4 million, down 24.23%, while the annual FY2025 figure was $11.4 million, 20.79% down from the prior year.
  • Prepaid Assets for Q1 2026 was $10.4 million at Zentalis Pharmaceuticals, down from $11.4 million in the prior quarter.
  • Over five years, Prepaid Assets peaked at $24.3 million in Q2 2022 and troughed at $7.6 million in Q3 2025.
  • A 5-year average of $14.6 million and a median of $13.8 million in 2025 define the central range for Prepaid Assets.
  • On a YoY basis, Prepaid Assets climbed as much as 51.73% in 2023 and fell as far as 48.08% in 2023.
  • Year by year, Prepaid Assets stood at $14.6 million in 2022, then surged by 41.58% to $20.6 million in 2023, then plummeted by 30.16% to $14.4 million in 2024, then dropped by 20.79% to $11.4 million in 2025, then fell by 8.53% to $10.4 million in 2026.
  • Business Quant data shows Prepaid Assets for ZNTL at $10.4 million in Q1 2026, $11.4 million in Q4 2025, and $7.6 million in Q3 2025.